These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. New oral anticoagulants might be useful thromboprophylactic agents in multiple myeloma patients on immunomodulatory agents. Aguilar C; Lucía JF Blood Coagul Fibrinolysis; 2010 Dec; 21(8):776-8. PubMed ID: 21042059 [No Abstract] [Full Text] [Related]
6. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Musallam KM; Dahdaleh FS; Shamseddine AI; Taher AT Thromb Res; 2009 Mar; 123(5):679-86. PubMed ID: 18992924 [TBL] [Abstract][Full Text] [Related]
7. Prevention and treatment of venous thromboembolism during pregnancy. Weitz JI Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S22-6. PubMed ID: 19213066 [TBL] [Abstract][Full Text] [Related]
8. Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients. Prandoni P; Samama MM Br J Haematol; 2008 May; 141(5):587-97. PubMed ID: 18422787 [TBL] [Abstract][Full Text] [Related]
9. [Venous thromboembolism prophylaxis in internal medicine]. Malý J; Widimský J; Dulícek P Vnitr Lek; 2009 Mar; 55(3):190-5. PubMed ID: 19378845 [TBL] [Abstract][Full Text] [Related]
10. Anticoagulation therapy for prevention and treatment of venous thromboembolic events in cancer patients: a review of current guidelines. Petersen LJ Cancer Treat Rev; 2009 Dec; 35(8):754-64. PubMed ID: 19762155 [TBL] [Abstract][Full Text] [Related]
11. Low-molecular-weight heparins for the prevention and treatment of venous thromboembolism in at-risk pregnant women: a review. Duhl AJ J Reprod Med; 2008 Sep; 53(9):657-66. PubMed ID: 18839817 [TBL] [Abstract][Full Text] [Related]
12. Thromboprophylaxis in multiple myeloma. Thalambedu N; Al Hadidi S Leuk Lymphoma; 2022 Dec; 63(12):2807-2815. PubMed ID: 35759648 [TBL] [Abstract][Full Text] [Related]
13. Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines. Lyman GH; Kuderer NM; Thromb Res; 2010 Apr; 125 Suppl 2():S120-7. PubMed ID: 20433991 [No Abstract] [Full Text] [Related]
14. Assessing the risk of venous thromboembolism in multiple myeloma. Sanfilippo KM Thromb Res; 2020 Jul; 191 Suppl 1():S74-S78. PubMed ID: 32736783 [TBL] [Abstract][Full Text] [Related]
15. First episode and recurrent venous thromboembolism: who is identifiably at risk? Liem TK; Deloughery TG Semin Vasc Surg; 2008 Sep; 21(3):132-8. PubMed ID: 18774448 [TBL] [Abstract][Full Text] [Related]
16. Updates on thrombotic events associated with multiple myeloma. Fotiou D; Gavriatopoulou M; Ntanasis-Stathopoulos I; Migkou M; Dimopoulos MA; Terpos E Expert Rev Hematol; 2019 May; 12(5):355-365. PubMed ID: 30957573 [TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials. Ageno W Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):569-76. PubMed ID: 19505271 [TBL] [Abstract][Full Text] [Related]